TY - JOUR
T1 - d-Cycloserine-Augmented Behavior Therapy for Body Dysmorphic Disorder
T2 - A Preliminary Efficacy Trial
AU - Weingarden, Hilary
AU - Mothi, Suraj S.
AU - Ladis, Ilana
AU - Hoeppner, Susanne
AU - Reese, Hannah E.
AU - Timpano, Kiara R
AU - Siev, Jedidiah
AU - Rasmussen, Jessica
AU - Ragan, Jennifer
AU - Dougherty, Darin D.
AU - Wilhelm, Sabine
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Cognitive behavioral therapy (CBT) is the leading psychotherapeutic treatment for body dysmorphic disorder (BDD), yet not all patients improve. To address the treatment response gap, CBT may be augmented with cognitive enhancers such as d-cycloserine (DCS). DCS-augmented behavior therapy has been tested with mixed results in related disorders. To initially test whether DCS may augment CBT for BDD, we conducted the first preliminary efficacy trial of DCS versus placebo-augmented CBT for BDD, via a randomized, double-blind study. We analyzed data using mixed-effects models in a modified intent-to-treat sample (N = 26). Over 10 weeks of treatment, primary (BDD severity) and secondary (insight, depression) outcomes improved significantly across both conditions, but there were no significant group differences in response. Exploratory analysis revealed that BDD-related distress, specifically, reduced significantly more in the DCS condition compared to placebo. This is the first study testing DCS-augmented CBT for BDD. Implications, limitations, and future directions are discussed. Trial registry: ClinicalTrials.gov Identifier NCT00842309.
AB - Cognitive behavioral therapy (CBT) is the leading psychotherapeutic treatment for body dysmorphic disorder (BDD), yet not all patients improve. To address the treatment response gap, CBT may be augmented with cognitive enhancers such as d-cycloserine (DCS). DCS-augmented behavior therapy has been tested with mixed results in related disorders. To initially test whether DCS may augment CBT for BDD, we conducted the first preliminary efficacy trial of DCS versus placebo-augmented CBT for BDD, via a randomized, double-blind study. We analyzed data using mixed-effects models in a modified intent-to-treat sample (N = 26). Over 10 weeks of treatment, primary (BDD severity) and secondary (insight, depression) outcomes improved significantly across both conditions, but there were no significant group differences in response. Exploratory analysis revealed that BDD-related distress, specifically, reduced significantly more in the DCS condition compared to placebo. This is the first study testing DCS-augmented CBT for BDD. Implications, limitations, and future directions are discussed. Trial registry: ClinicalTrials.gov Identifier NCT00842309.
KW - Behavior therapy
KW - Body dysmorphic disorder
KW - Cognitive enhancers
KW - d-Cycloserine
UR - http://www.scopus.com/inward/record.url?scp=85062637999&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062637999&partnerID=8YFLogxK
U2 - 10.1007/s10608-019-10015-0
DO - 10.1007/s10608-019-10015-0
M3 - Article
AN - SCOPUS:85062637999
JO - Cognitive Therapy and Research
JF - Cognitive Therapy and Research
SN - 0147-5916
ER -